Point72 Asset Management’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-2,573,700
| Closed | -$60.8M | – | 2735 |
|
|
2023
Q4 | $60.8M | Buy |
2,573,700
+143,776
| +6% | +$2.56M | 0.15% | 179 |
|
|
2023
Q3 | $36.2M | Buy |
+2,429,924
| New | +$32.2M | 0.11% | 250 |
|
|
2023
Q2 | – | Sell |
-20,597
| Closed | -$180K | – | 2924 |
|
|
2023
Q1 | $180K | Buy |
+20,597
| New | +$165K | ﹤0.01% | 1514 |
|
|
2022
Q3 | – | Sell |
-350,000
| Closed | -$1.03M | – | 1808 |
|
|
2022
Q2 | $1.03M | Buy |
+350,000
| New | +$836K | ﹤0.01% | 1068 |
|
|
2022
Q1 | – | Sell |
-681,401
| Closed | -$2.3M | – | 1444 |
|
|
2021
Q4 | $2.3M | Buy |
+681,401
| New | +$2.59M | 0.01% | 802 |
|
|
2020
Q3 | – | Sell |
-576,638
| Closed | -$2.01M | – | 1137 |
|
|
2020
Q2 | $2.01M | Buy |
+576,638
| New | +$1.66M | 0.01% | 589 |
|
|
2019
Q4 | – | Sell |
-3,160,600
| Closed | -$16.2M | – | 1317 |
|
|
2019
Q3 | $16.2M | Sell |
3,160,600
-738,030
| -19% | -$4.47M | 0.1% | 255 |
|
|
2019
Q2 | $27.9M | Buy |
+3,898,630
| New | +$44.1M | 0.15% | 179 |
|
|
2019
Q1 | – | Sell |
-219,715
| Closed | -$1.73M | – | 1283 |
|
|
2018
Q4 | $1.73M | Buy |
219,715
+145,518
| +196% | +$1.39M | 0.01% | 735 |
|
|
2018
Q3 | $822K | Buy |
+74,197
| New | +$922K | ﹤0.01% | 864 |
|
|
2016
Q2 | – | Sell |
-843,800
| Closed | -$1.14M | – | 909 |
|
|
2016
Q1 | $1.14M | Sell |
843,800
-191,488
| -18% | -$237K | 0.01% | 613 |
|
|
2015
Q4 | $1.75M | Hold |
1,035,288
| – | – | 0.01% | 564 |
|
|
2015
Q3 | $2.01M | Buy |
1,035,288
+450,000
| +77% | +$1.23M | 0.02% | 560 |
|
|
2015
Q2 | $1.57M | Hold |
585,288
| – | – | 0.01% | 589 |
|
|
2015
Q1 | $4.05M | Buy |
585,288
+14,200
| +2% | +$136K | 0.03% | 467 |
|
|
2014
Q4 | $5.61M | Buy |
+571,088
| New | +$4.59M | 0.04% | 416 |
|
Other funds holding CBAY
Point72 Asset Management's CBAY Position: Q1 2024 in Review
Point72 Asset Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 2,573,700 shares — an estimated $60.8M sold.
Point72 Asset Management first reported a position in CBAY in Q4 2014 and held it in 16 quarters. The position peaked at $60.8M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Point72 Asset Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Point72 Asset Management sold 2,573,700 Cymabay Therapeutics shares in Q1 2024, an estimated $60.8M.
- Point72 Asset Management first reported a position in Cymabay Therapeutics in Q4 2014 and held it in 16 quarters.
- Point72 Asset Management's Cymabay Therapeutics position peaked at $60.8M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Point72 Asset Management's 13F filing for Q1 2024, filed 15 May 2024.